News Sentiment

NTHI sentiment intelligence

NeOnc Technologies Holdings, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.46 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-22.9% over one week, -34.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to EBITDA forward of NeOnc Technologies Holdings, Inc. – NASDAQ:NTHI

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -22.9% Price reacting lower
Trend fit Trend inactive -34.3% over four weeks
Fair value -53.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 39
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 10
TradingView 9
Moomoo 3
Sahm 2
Investing.com Nigeria 2
Investing.com 2
marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 19
Regulatory and legal 8
Analyst action 3
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
TradingView Direct company coverage

Enterprise value to EBITDA forward of NeOnc Technologies Holdings, Inc. – NASDAQ:NTHI

This article provides the enterprise value to EBITDA forward for NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). It appears to be a financial data point from TradingView, indicating a specific metric for the company's valuation. The content itself seems to be a display of this

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 21:10
Source
TradingView
Sahm Direct company coverage

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Technologies Holdings, Inc. announced receipt of detailed written feedback from the FDA regarding the chemistry, manufacturing and controls (CMC) development program for its drug NEO212, and the planned transition from a capsule to a tablet formulation. The feedback clarifi

Tone
Positive 67/100
Event
Market update
Published
16 Jul 2026 10:41
Source
Sahm
Moomoo Direct company coverage

NEONC TECHNOLOGIES - TO UPDATE NEO212 DEVELOPMENT PLAN AFTER INCORPORATING FDA FEEDBACK

NEONC Technologies plans to update its NEO212 development plan following feedback from the FDA. This indicates a key regulatory step in advancing their product. The company aims to refine its strategy to align with the FDA's requirements.

Tone
Positive 66/100
Event
Regulatory and legal
Published
15 Jul 2026 21:10
Source
Moomoo
Moomoo Direct company coverage

Neonc Technologies - Cancels July 9 FDA Meeti

This article provides a brief but critical update regarding Neonc Technologies. The company has announced the cancellation of its previously scheduled FDA meeting on July 9. Further details or implications of this cancellation are not provided in this snippet.

Tone
Negative 15/100
Event
Market update
Published
15 Jul 2026 20:40
Source
Moomoo
Investing.com Direct company coverage

NeOnc receives FDA feedback on NEO212 manufacturing requirements

NeOnc Technologies Holdings, Inc. received written feedback from the FDA regarding manufacturing requirements for its drug NEO212, streamlining the development process by clarifying chemistry, manufacturing, and controls aspects. Despite recent stock volatility and being near its

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 13:13
Source
Investing.com
Stock Titan Direct company coverage

FDA Says NEO212 Drug-Product Plan May Run Alongside Late-Stage Trials

NeOnc Technologies received detailed written feedback from the FDA regarding the chemistry, manufacturing, and controls (CMC) program for its drug, NEO212, which enabled them to cancel their Type B End-of-Phase 1 meeting. The FDA's feedback indicated that the proposed CMC develop

Tone
Positive 64/100
Event
Market update
Published
15 Jul 2026 13:13
Source
Stock Titan
TradingView Direct company coverage

NeOnc receives FDA CMC feedback on NEO212; capsule-to-tablet bioavailability study advised

NeOnc has received detailed FDA feedback on the Chemistry, Manufacturing, and Controls (CMC) development for NEO212, along with guidance for transitioning from a capsule to a tablet formulation. The FDA found NeOnc's development approach reasonable and recommended an in vivo rela

Tone
Positive 62/100
Event
Guidance
Published
15 Jul 2026 13:13
Source
TradingView
Stock Titan Direct company coverage

NeOnc Technologies (NASDAQ: NTHI) receives detailed FDA CMC feedback on NEO212

NeOnc Technologies Holdings, Inc. announced it received detailed written feedback from the FDA regarding the chemistry, manufacturing, and controls (CMC) development program for its drug candidate NEO212. The FDA's feedback covers manufacturing, formulation, bioavailability, and

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 13:13
Source
Stock Titan
Simply Wall Street Direct company coverage

Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off

Insiders at NeOnc Technologies Holdings have purchased US$615.6k worth of shares over the past year at an average price of US$5.51, which has since decreased to US$411.4k due to a 15% stock decline. Despite the loss, recent insider buying, particularly US$138k in the last quarter

Tone
Positive 66/100
Event
Earnings
Published
15 Jul 2026 11:13
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Form 4 Neonc Technologies Holdings Inc For: 13 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Neonc Technologies Holdings Inc. related to activity on July 13. The brief piece indicates that financial markets worldwide are covered by Investing.com, hinting at the regulatory filing's relevance within broader fin

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 22:13
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Neonc Technologies (NTHI) director discloses holding 160 common shares

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) director SHOMALI NASIM reported direct ownership of 160 shares of Common Stock as of July 1, 2026. This Form 3 filing indicates a holding entry with no reported purchases, sales, or derivative positions. The report clarifies that SHOMALI N

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

NEONC Technologies (NTHI) awards director 50,000 restricted shares

NEONC Technologies (NTHI) announced that director Nasim Shomali was granted 50,000 restricted shares of common stock on July 10, 2026, under the company’s 2023 Equity Incentive Plan. These shares will vest 100% six months from the grant date, increasing Shomali's direct holdings

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

New NeOnc (NASDAQ: NTHI) director is CEO's niece

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) announced changes to its Board of Directors. Ming-Fu (Alan) Chiang resigned, and Nasim Shomali was elected as a Class II director, effective July 1, 2026. The company disclosed that Ms. Shomali is the niece of President, CEO, and E

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 06:40
Source
Stock Titan
TradingView Direct company coverage

NeOnc Technologies Holdings, Inc. Financial Disclosures & SEC Filings

This page provides access to NeOnc Technologies Holdings, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. Recent filings detail clinical progress, financial performance, funding activities like PIPE financing, and financial challenges such a

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 18:12
Source
TradingView
Quartr Direct company coverage

NeOnc Technologies Holdings (NTHI) Investor Relations, Earnings Summary & Outlook

NeOnc Technologies Holdings (NTHI) reported a Q1 2026 net loss of $8.8 million, a significant decrease from Q1 2025. The company advanced two clinical programs in CNS cancers, NEO212 and NEO100, with interim data for NEO100 expected in August 2026. NTHI secured $10 million in PIP

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 22:10
Source
Quartr
marketscreener.com Direct company coverage

NeOnc Technologies Holdings, Inc.(NasdaqGM:NTHI) dropped from Russell 3000E Growth Benchmark

NeOnc Technologies Holdings, Inc. (NasdaqGM:NTHI), a clinical-stage biopharmaceutical company focusing on intracranial malignancies, has been dropped from the Russell 3000E Growth Benchmark. This news comes amidst other recent announcements regarding the company, including securi

Tone
Negative 36/100
Event
Market update
Published
29 Jun 2026 16:10
Source
marketscreener.com
marketscreener.com Direct company coverage

NeOnc Technologies Holdings, Inc.(NasdaqGM:NTHI) dropped from Russell Microcap Growth Benchmark Index

NeOnc Technologies Holdings, Inc. (NasdaqGM:NTHI) has been removed from the Russell Microcap Growth Benchmark Index. This news follows other recent announcements regarding the company, including securing funding and receiving UAE IND approval for its drug candidates, NEO100 and N

Tone
Neutral 50/100
Event
Regulatory and legal
Published
29 Jun 2026 03:39
Source
marketscreener.com
TradingView Direct company coverage

NTHI Forecast — Price Target — Prediction for 2027

This article provides a price forecast for NeOnc Technologies Holdings, Inc. (NTHI) based on analyst opinions, with a max estimate of $20.00 and a min estimate of $13.00. It also covers the stock's current price, historical performance, volatility, market capitalization, and upco

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

NeOnc Technologies Holdings, Inc. Actuals & Estimates (NASDAQ:NTHI)

This article provides an overview of NeOnc Technologies Holdings, Inc. (NTHI) stock, including its current price, historical performance, analyst forecasts, and financial details. It covers various metrics such as market capitalization, earnings, EBITDA, and volatility, and addre

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:10
Source
TradingView
TradingView Direct company coverage

NeOnc Technologies Holdings, Inc. Actuals & Estimates (BOATS:NTHI)

This article provides financial actuals and estimates for NeOnc Technologies Holdings, Inc. (NTHI), including income statement, balance sheet, and cash flow data. It addresses frequently asked questions about the stock, such as its ticker, analyst forecasts, historical prices, ea

Tone
Negative 40/100
Event
Analyst action
Published
25 Jun 2026 17:09
Source
TradingView
Stock Titan Direct company coverage

[EFFECT] NEONC TECHNOLOGIES HOLDINGS, INC. SEC Filing

This article reports on an SEC filing from NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI), specifically an EFFECT filing for Form S-3, which became effective on June 23, 2026. The filing indicates a "Neutral" impact and sentiment. The article also provides company overview data, recent

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 01:09
Source
Stock Titan
Stock Titan Direct company coverage

NeOnc Technologies (Nasdaq: NTHI) wins UAE IND for NEO100 ahead Phase 2a data

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) has received Investigational New Drug (IND) status from the Department of Health – Abu Dhabi for its lead candidate, NEO100. This authorization covers multiple protocols and phases for adult and pediatric studies targeting high-gra

Tone
Positive 67/100
Event
Regulatory and legal
Published
24 Jun 2026 15:40
Source
Stock Titan
Sahm Direct company coverage

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc Technologies has received Investigational New Drug (IND) approval from the Department of Health – Abu Dhabi (DOH) for its lead candidate, NEO100, for the treatment of progressive or recurrent Grade III or IV gliomas. This authorization covers all three NEO100 programs acros

Tone
Positive 87/100
Event
Regulatory and legal
Published
24 Jun 2026 14:41
Source
Sahm
Moomoo Direct company coverage

NeOnc Technologies Holdings Secures Second UAE IND Authorization for NEO100, Expanding Global CNS Cancer Development Program

NeOnc Technologies Holdings has secured its second Investigational New Drug (IND) authorization in the UAE for NEO100, its lead intranasal therapy for recurrent high-grade gliomas, broadening its global CNS cancer development programs. This authorization covers adult and pediatri

Tone
Positive 82/100
Event
Regulatory and legal
Published
24 Jun 2026 13:39
Source
Moomoo
Stock Titan Direct company coverage

NeOnc wins another UAE clearance as brain-cancer data nears

NeOnc Technologies (NASDAQ:NTHI) has secured a second UAE IND authorization for its lead intranasal therapy NEO100, targeting recurrent high-grade gliomas, with Phase 2a data expected by the end of July 2026. This expands NeOnc's international development framework, complementing

Tone
Positive 66/100
Event
Market update
Published
24 Jun 2026 13:39
Source
Stock Titan